CRISPR Therapeutics AG — Director's Dealing 2017

Aug 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-08-28

Reporting Person: Kulkarni Samarth (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-28	Common Shares	S	23154	$20.0899	Disposed	110893	Direct
2017-08-30	Common Shares	S	4000	$20.00	Disposed	106893	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transaction at prices ranging from $20.00 to $20.25, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff at the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price.